But in the meantime, parents in the United States have no place to enroll in a FDA-approved program of cell therapy to treat ASD. If the results of that study are good, they could justify a new Expanded Access program. At the same time, Duke has obtained additional funding to complete their IMPACT trial NCT04089579, a phase 2 study of umbilical cord mesenchymal stromal cells (UC-MSC) as therapy for ASD. The program is still running for children with brain injury conditions such as Cerebral Palsy, HIE, etc. Update: At the end of 2022, Duke University stopped treating children with Autism Spectrum Disorder (ASD) on their program of Expanded Access to cord blood therapies. The Foundation's Terms of Use is expressly incorporated herein. The Foundation is not liable for any damages of any kind, nature or description (whether direct, consequential or punitive) arising out of or relating to information referenced in the Newsletter, or related in any way to the user's access to the Newsletter. Access to and use of all Newsletter information is at the user's own risk. The Foundation reserves the right at any time to remove materials and information from the Newsletter without communication with the author or organization. The Foundation is not responsible for the accuracy and completeness of information provided by guest authors, outside sources, or on websites linked to the Newsletter. The materials and information included in this electronic newsletter (Newsletter), including advertisements, are provided as a service to you and do not reflect endorsement by the Parent's Guide to Cord Blood Foundation (the "Foundation").
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |